Comparison of Chemotherapy Response and Adverse Effects of Double-Platinum Plus Egfr-Tki Versus Double-Platinum Alone on NSLCLC Patients With Disease Progression and Egfr-Tki Treatment

Abstract

ABSTRAK EGFR-TKI adalah terapi lini pertama untuk pasien mutan EGFR. Namun, pasien akan mengalami perkembangan penyakit KKE/I/2017). Hasil penelitian menunjukkan bahwa karakteristik subjek antara dua lengan berbeda secara signifikan (p=0,05). Mutasi EGFR yang paling umum adalah ekson 21 (50% pada lengan A dan 60% pada lengan B). Uji kuadrat diuji pada parameter respon subyektif (EQ5D (p=0,483)). Sampel bebas T2 diuji pada parameter semi subyektif (berat badan (p=1.00)). Uji EGFR-TKI is the first-line therapy for EGFR-mutant patients. Nevertheless, patients will have disease progression (median PFS 10 -12 months) due to resistance. The treatment options are still limited in developing countries for such cases, thus double-platinum chemotherapy is the next option. Although IMPRESS study reported no difference in terms of PFS and OS between double-platinum alone and double-platinum plus EGFR-TKI, several local studies reported benefit of continuing EGFR-TKI in combination with double-platinum chemotherapy (treatment beyond progression). This study aimed to compare chemotherapy effects of doubleplatinum plus EGFR-TKI versus double-platinum alone on patients with NSCLC progression after EGFR-TKI treatment. This was an analytical descriptive study using prospective cohort design, involving 30 patients with disease progression following EGFR-TKI treatment that met inclusion criteria in Dr. Soetomo Hospital. Subjects were divided into two groups: arm A (double-platinum plus EGFR-TKI) and arm B (double-platinum alone

The Profile of Lung Adenocarcinoma Patients with Positive EGFR Mutation

“…This is consistent with research in Wulandari, 2017, which is the subject of research in general women and the age range of 50 years. 1,8,9 This research subject is NSCLC patients who undergo positive EGFR mutation and patients dominate smokers than non-smokers. This is not following the IPASS study found that lung adenocarcinoma predominantly occurs in nonsmokers than smoker.…”

“…Its study result also has the same with previous research, whre a group of nonsmokers patients tends to have positive EGFR mutation. 1,2,10 Smoking is the cause of 85-90% of all lung cancer cases. , SVCS (4%), dysphagia (2%), wheezing and stridor (2%).…”

“…, SVCS (4%), dysphagia (2%), wheezing and stridor (2%). 1,4,5 The whole sample of this study are patients with lung adenocarcinoma with EGFR positive mutation, and EGFR exon 19 was the most common type. In EGFR exon 21 type, L858R mutation was predominantly.…”

“…The incidence of new cases of lung cancer in the United States ranks second only to breast cancer, which is estimated at 224,390 cases in 2016, or approximately 13% of all cancer diagnoses occur 158,080 deaths in 2016 is about 27% of all cancer deaths. 1,2 The incidence of lung cancer in Indonesia tends to increase. Data and information center of the Ministry of Health showed that the incidence of lung cancer in the Cancer Hospital Dharmais in 2013 ranks third after breast cancer and cervical cancer in the amount of 173 cases or 7% of all cancers and deaths from lung cancer by 65 cases or 12% of of all cancer deaths.…”